Pharma Export from India: A 2026 Market & Compliance Guide
The scale of India's pharmaceutical export industry, the licence stack a compliant exporter operates under, and how destination market tiers determine what's realistic — in one reference.
India is the world's third-largest drug producer by volume and supplies roughly a fifth of global generic medicine. In FY 2024–25, Indian pharmaceutical exports reached $30.4 billion, up 9.4% year-on-year, with formulations and biologicals accounting for 75.7% of that value across more than 200 destination countries. The scale is real — and so is the competition, which is why differentiation by category, corridor and documentation quality matters more than price alone.
The single fact that shapes every legitimate export business
Direct-to-consumer export of prescription medicine is illegal into almost every market worth selling to. This isn't a grey area — regulators including the US FDA treat unsolicited commercial shipment of prescription drugs to consumers as drug importation without approval, and it has produced criminal convictions of India-based operators. The legal, scalable route is B2B: selling to licensed importers, wholesalers, hospital groups and government tenders who hold the import authorisation in their own country. That is the model this platform, and the wider $30 billion legitimate export industry, actually runs on.
The licence stack, in brief
- Company incorporation, PAN and current account
- Importer-Exporter Code (IEC) from DGFT
- Wholesale drug licence — Form 20B (general) and 21B (biologicals/injectables)
- RCMC from Pharmexcil
- AD Code registration and ICEGATE customs filing
- COPP / WHO-GMP certificate (held by the manufacturing partner for a merchant exporter)
- Export NOC from CDSCO, where the specific product category requires one
- Destination-country product registration — the step that usually takes the longest
Market tiers, not one global market
Destination regulators, not Indian ones, set the real timeline for any export relationship. Highly regulated markets (the US, EU, UK, Japan) require a USFDA- or EU-GMP-inspected facility and a multi-year dossier process for finished formulations. Semi-regulated markets (Brazil, Mexico, Russia, the Gulf states, South Africa) generally accept a WHO-GMP and COPP dossier alongside their own registration process, typically 12–36 months. Emerging markets across Africa, South-East Asia and parts of Latin America accept a lighter CTD dossier plus COPP, often in 4–18 months — the realistic starting corridor for a new export relationship. Nutraceuticals, AYUSH, cosmetics and Class A medical devices require no drug registration at all in most markets, making that the one category where genuine direct-to-consumer trade is legal worldwide.
What this means for buyers
If you're a licensed importer, wholesaler or institutional buyer evaluating an Indian supply partner, the questions worth asking are: which manufacturing partner actually holds the WHO-GMP/COPP for the specific product, what documentation set travels with the consignment, and whether the export status of your specific product and destination has been checked against the current DGFT notification — not assumed from a general product listing. See our Compliance page for how we handle each of these.